| WBC | 4.5 | | 4.0 - 11.0 k/mm3 |
| RBC | 5.18 | | 4.30 - 6.00 m/mm3 |
| Hemoglobin | 16.5 | | 13.5 - 17.0 g/dL |
| Hematocrit | 48.8 | | 40.0 - 53.0 % |
| MCV | 94.2 | | 78.0 - 100.0 fL |
| MCH | 31.9 | | 27.0 - 34.0 pg |
| MCHC | 33.8 | | 31.0 - 37.0 g/dL |
| Platelet Count | 268 | | 130 - 450 k/mm3 |
| RDW(sd) | 45.7 | | 38.0 - 49.0 fL |
| RDW(cv) | 13.2 | | 11.0 - 15.0 % |
| MPV | 10.3 | | 9.0 - 12.0 fL |
| Segmented Neutrophils | 66.9 | | % |
| Automated Diff | | | |
| Lymphocytes | 20.3 | | % |
| Monocytes | 10.4 | | % |
| Eosinophils | 2.0 | | % |
| Basophils | 0.2 | | % |
| Absolute Neutrophil | 3.0 | | 1.5 - 7.8 k/uL |
| Absolute Lymphocyte | 0.9 | | 0.9 - 3.9 k/uL |
| Absolute Monocyte | 0.5 | | 0.2 - 1.0 k/uL |
| Absolute Eosinophil | 0.1 | | 0.0 - 0.6 k/uL |
| Absolute Basophil | 0.0 | | 0.0 - 0.2 k/uL |
| Immature Granulocytes | 0.2 | | % |
| Absolute Immature Granulocytes | 0.0 | | 0.0 - 0.1 k/uL |
| NRBC RE, Nucleated Red Blood Cell Percent | 0.0 | | 0.0 - 1.0 % |
38055 - TSH with Reflex Free T4
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| TSH, High Sensitivity | 1.58 | | 0.27 - 4.20 mU/L |
9201 - Estradiol Total
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| Estradiol Total | 64* | H | <=44 pg/mL |
Estradiol Reference Ranges:
Estradiol Adult Reference Ranges:
Follicular: 12-233 pg/mL
Ovulation: 41-398 pg/mL
Luteal: 22-341 pg/mL
Postmenopausal: <139 pg/mL
Pregnancy (1st Trimester): 154-3243 pg/mL
Pregnancy (2nd Trimester): 1561-21280 pg/mL
Pregnancy (3rd Trimester): >8525 pg/mL
Male Reference Range: <45 pg/mL
No reference ranges established for pediatric patients. | | | |
907280 - Testosterone, Free, Total, and Bioavailable (Adult Males)
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| Testosterone, Total | 2613* | H | 240 - 1022 ng/dL |
| Testosterone, Bioavailable | 1925.1* | H | 61.0 - 257.0 ng/L |
| Testosterone, Free | 722.2* | H | 35.0 - 155.0 pg/mL |
Free and bioavailable testosterone was derived using a mass-action
equation that employs defined constants for the binding of
testosterone to albumin and sex-hormone binding globulin (Clin Chem.
2006; 52(9): 1777-1784). | | | |
900323 - Comprehensive Metabolic Panel
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| Glucose | 86 | | 70 - 99 mg/dL |
| Glucose reference range reflects fasting state. | | | |
| Urea Nitrogen (BUN) | 12 | | 7 - 21 mg/dL |
| Creatinine | 1.17 | | 0.68 - 1.37 mg/dL |
| eGFRcr CKD-EPI | 90 | | >=60 mL/min/1.73m2 |
| eGFRcr calculated using the CKD-EPI 2021 equation | | | |
| BUN/Creatinine Ratio | 10.3 | | 10.0 - 28.0 |
| Sodium | 138 | | 135 - 145 mmol/L |
| Potassium | 4.2 | | 3.6 - 5.3 mmol/L |
| Chloride | 100 | | 98 - 108 mmol/L |
| Carbon Dioxide (CO2) | 27 | | 20 - 31 mmol/L |
| Anion Gap | 11 | | 4 - 18 |
| Protein, Total | 7.2 | | 6.3 - 8.0 g/dL |
| Albumin | 4.9 | | 3.8 - 5.1 g/dL |
| Globulin | 2.3 | | 1.7 - 3.3 g/dL |
| Albumin/Globulin Ratio | 2.1 | | 1.3 - 2.7 |
| Calcium | 9.9 | | 8.7 - 10.4 mg/dL |
| Alkaline Phosphatase | 115 | | 40 - 140 IU/L |
| Alanine Aminotransferase | 41 | | 5 - 60 IU/L |
| Aspartate Aminotransferase | 34 | | 12 - 47 IU/L |
| Bilirubin, Total | 2.0* | H | <=1.2 mg/dL |
1877 - Lipid Panel
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| Cholesterol | 115 | | <=199 mg/dL |
| Triglycerides | 47 | | <=149 mg/dL |
| Cholesterol/HDL Ratio | 3.0 | | <=4.9 |
| HDL Cholesterol | 38* | L | >=40 mg/dL |
| Non-HDL Cholesterol | 77 | | <=129 mg/dL |
| LDL Cholesterol, Calculated | 67 | | <=99 mg/dL |
LDL-C is calculated by using the Martin-Hopkins equation. (JAMA.
2013;310(19):2061-2068)
For moderately high risk and high risk cardiac patients, reference
levels of <100 mg/dL and <70 mg/dL, respectively, should be
considered. Circulation 2004; 110:227-239. | | | |
| VLDL Cholesterol | 10 | | <=29 mg/dL |
9230 - Hemoglobin A1c With eAG
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| Hemoglobin A1c | 4.9 | | <=5.6 % |
The American Diabetes Association (ADA) guidelines for interpreting
Hemoglobin A1c are as follows:
Non-Diabetic patient: <=5.6%
Increased risk for future Diabetes: 5.7-6.4%
ADA diagnostic criteria for Diabetes: >=6.5%
For most patients, a reasonable goal for therapy is <7%. For patients
with limited life expectancy or where the harms of treatment are
greater than the benefits, a goal of <8% may be more appropriate. In
pregnant patients, a more stringent goal of <6% may be appropriate or
<7% if there is a risk of hypoglycemia. Diabetes Care. 2023; 46(Suppl
1):S254-S266. | | | |
| Estimated Average Glucose (eAG) | 94 | | Not Established |
If the presence of a hemoglobin variant is suspected, do not use %
HbA1c results for diagnosis of diabetes mellitus.
In uncontrolled diabetics, high levels of Hemoglobin F (Hb F) may be
present. Presence of Hb F greater than 7% of total may result in
lower than expected % HbA1c.
Any cause that shortens erythrocyte survival or decreases mean
erythrocyte age may reduce expected % HbA1c values even in the
presence of elevated average blood glucose. Causes may include
hemolytic disease, homozygous sickle cell trait, pregnancy, and
recent significant/chronic blood loss. In addition, recent blood
transfusions can alter expected % HbA1c values. | | | |
1054 - RPR Screen w/Reflex RPR Titer and TP-PA
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| RPR Screen | Nonreactive | | Nonreactive |
3682 - HIV 1/2 Ag and Abs, Fourth Generation, w/Reflexes
Reported8/12/2026 1:59 AMStatusFinalLab NameSonora Quest Laboratories - Tempe
| Test Name | Result | Flags | Reference Range |
|---|
| HIV 1/2 Screen (CHIV) | Nonreactive | | Nonreactive |
Negative for HIV-1 antigen and HIV-1/HIV-2 antibodies. No laboratory
evidence of HIV infection. | | | |